|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A House Energy & Commerce subcommittee is wrapping up a meeting today on the FDA's role in advancing US drug development. While no FDA officials are testifying at the hearing, the topic is an important one as the agency has typically led the world in drug approvals in terms of speed and quantity. But how many new FDA incentives will be necessary to help the US compete with China? That remains an open question. Check out Max's coverage below on a bipartisan measure that would throw cold water on US biotech companies trying to strike deals with Chinese firms. |
|
|
|
Zachary Brennan |
Senior Editor, Endpoints News
@ZacharyBrennan
|
|
|
|
|
|
|
by Zachary Brennan
|
The FDA on Friday posted 14 new rejection letters to pharma companies online, days after HHS confirmed to Endpoints Newsthat the agency had paused... | |
|
|
|
|
|
|
by Zachary Brennan
|
The FDA's drug center hired more new employees than it lost in a quarter for the first time since the Trump administration gutted the agency's... | |
|
|
|
 |
|
|
|
by Max Bayer
|
After setting the industry ablaze last month, a bipartisan bill aimed at restricting US biotech companies from striking deals with Chinese counterparts is in limbo... | |
|
|
|
|
|
|
by Anna Brown
|
The FDA is proposing a rule to change how factories are registered with the agency if they are making products for the US market, as... | |
|
|
|
 |
|
|
|
by Max Bayer
|
The FDA has finalized clinical guidance for psychedelic drug developers and has scheduled a public hearing on future therapeutic use, adding regulatory momentum to a... | |
|
|
|
|
|
|
by Zachary Brennan
|
The FDA has chastised Lundbeck Seattle Biopharmaceuticals for two promotional webpages that made allegedly inflated claims regarding the efficacy of its migraine drug. In an ... | |
|
|
|
|
|